The genomic test can theoretically apply to any cancer, but the Duke team focused on lung cancer because the survival rate is only 15 % of lung cancer. Now kills more Americans each year together more than breast, prostate and colon cancer.
About RegeneRx Biopharmaceuticals,is RegeneRx to accelerate repair on the discovery and development of novel peptides for tissue and organ damage is concentrated. Currently RegeneRx developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic and cardiovascular tissue repair, each. This product WILEX are based on T? a 43 – amino acid, naturally occurring peptide, in part through an exclusive worldwide license from the National Institutes of Health. In the U.S. Over 60 worldwide patents and patent applications relating to novel peptides and is currently sponsoring three Phase II chronic dermal wound healing clinical Phase II until a wound ophthalmic therapeutic clinical trial phase I and parenteral clinical trial supporting systemic delivery of 352 RGN reduce heart damage in patients after acute myocardial infarction, in addition to other systemic indications..CT Colonography Is this an exact trial?Suggest new insights of a multi center study for the accuracy of the colonoscopy it identify 75 to 85 % middle and large polyps. It is not as accurate identifying small polyps who also the potential develop in order Krebs. Past studies to colonoscopy had demonstrated a very wide range results. Studies. Results so far have shown to colonoscopy been clearly unsuccessful colonoscopy for detection of colon polyps, with many false negative and false positive results.